Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy

NCT02711007 is registered in ClinicalTrials.gov with GUO WEI as lead sponsor.

NCT NCT02711007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02711007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy
Lead sponsor
GUO WEI
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2016
Completion date
January 8, 2018
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis, osteosarcoma